Literature DB >> 15510162

Hallmarks of 'BRCAness' in sporadic cancers.

Nicholas Turner1, Andrew Tutt, Alan Ashworth.   

Abstract

Germline mutations in the BRCA1, BRCA2 and Fanconi anaemia genes confer cancer susceptibility, and the proteins encoded by these genes have distinct functions in related DNA-repair processes. Emerging evidence indicates that these processes are disrupted by numerous mechanisms in sporadic cancers. Collectively, there are properties that define 'BRCAness' - that is, traits that some sporadic cancers share with those occurring in either BRCA1- or BRCA2-mutation carriers. These common properties might have important implications for the clinical management of these cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15510162     DOI: 10.1038/nrc1457

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  612 in total

1.  Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.

Authors:  Arnaldo A Arbini; Margherita Greco; Jorge L Yao; Patricia Bourne; Ersilia Marra; Jer-Tsong Hsieh; Paul A di Sant'agnese; Loredana Moro
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  From the bench to the bed: individualizing treatment in non-small-cell lung cancer.

Authors:  Mariacarmela Santarpia; Giuseppe Altavilla; Fernanda Salazar; Miquel Tarón; Rafael Rosell
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

Review 3.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

4.  The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Authors:  M Javle; N J Curtin
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 5.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

6.  Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.

Authors:  Elizabeth M Swisher; Toshiyasu Taniguchi; Beth Y Karlan
Journal:  J Natl Cancer Inst       Date:  2012-04-13       Impact factor: 13.506

7.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Authors:  Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2012 Jan-Feb

8.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 9.  DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Authors:  Henning Willers; Liliana Gheorghiu; Qi Liu; Jason A Efstathiou; Lori J Wirth; Mechthild Krause; Cläre von Neubeck
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

Review 10.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.